Mineralys Therapeutics

NCT06785454

Phase 2, Completed, 2025, 48 people, 21 Jan 2025, clinicaltrials.gov

NCT06150924

Phase 2, Completed, 2023, 60 people, 29 Nov 2023, clinicaltrials.gov

NCT05968430

Phase 3, Active, not recruiting, 2023, 1,076 people, 1 Aug 2023, clinicaltrials.gov

Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension

Grants or research support, 6 Aug 2026, pubmed.ncbi.nlm.nih.gov